A Conversation with Alector’s Vice President of Clinical Development
Earlier this year, the biopharmaceutical company Alector announced that the U.S. Food and Drug Administration (FDA) had granted a “breakthrough therapy designation” to latozinemab, the company’s investigational drug designed to address FTD caused by a variant in the GRN gene. The special designation enables expedited regulatory review of therapies intended to treat serious conditions. A…
Read MoreVesper Bio Announces Successful Completion of Phase 1 Study for Potentially Disease-Modifying Treatment for FTD-GRN
Biotechnology company Vesper Bio announced in early September that the phase 1 clinical trial for its potentially disease-modifying treatment for FTD-GRN has successfully concluded. The company noted data from the trial demonstrated excellent safety and tolerability of the orally administered drug VES001. In FTD caused by an inherited GRN mutation, the production of the essential…
Read MoreNovember 24, 2024: In-Person Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. The event will take place from 7:30 a.m. – 12:00 p.m. on November 24 at St. Catherine of Siena…
Read MoreIn-Person Meet & Greet in Manchester, NH
Join and learn from others who understand the FTD journey at this in-person AFTD Meet & Greet event, hosted by AFTD Ambassador Shirley Gordon and Kevin Rhodes, co-chair of the AFTD Persons with FTD Advisory Council. RSVP for this event by emailing sgordon@theaftd.org. To learn more, download this flyer.
Read MoreOhio Hybrid Caregiver Lunch and Learn: Frontotemporal Dementia
Bring a lunch and join AFTD Ambassador Judy Bearer for this lunch-and-learn event about frontotemporal degeneration (FTD), the most common cause of dementia in adults under 60 (though it can strike adults at any age). We will review possible causes and symptoms, find local resources, and learn how we can best support those affected by…
Read MoreAFTD Webinar: Diagnosing Primary Progressive Aphasia
With primary progressive aphasia (PPA), problems with language and communication typically deteriorate gradually over time. Initial symptoms are sometimes attributed to anxiety or stress until the ongoing symptoms become disruptive enough to prompt further assessment by a specialist. This webinar is intended for clinicians to support early detection and accurate diagnosis of PPA. Learners will…
Read More
English 
Spanish (Mexico) 
French 
German 
Swedish 
Portuguese 
Italian 
Dutch 
Danish 
Polish 
Spanish (Spain)